Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection
Biochemical Society Transactions · 26.06.2024 · 52 (3) · 1515-1528
DOI: 10.1042/bst20231547 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 08.05.2024. Verfasst von Wei Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: VPD Heart and Lung Research Institute, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0BB, U.K. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein Receptors, Type II, Signal Transduction, Bone Morphogenetic Proteins, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a rare and life-threatening vascular disorder, characterised by abnormal remodelling of the pulmonary vessels and elevated pulmonary artery pressure, leading to right ventricular hypertrophy and right-sided heart failure. The importance of bone morphogenetic protein (BMP) signalling in the pathogenesis of PAH is demonstrated by human genetic studies. Many PAH risk genes are involved in the BMP signalling pathway and are highly expressed or preferentially act on vascular endothelial cells. Endothelial dysfunction is recognised as an initial trigger for PAH, and endothelial BMP signalling plays a crucial role in the maintenance of endothelial integrity. BMPR2 is the most prevalent PAH gene, found in over 80% of heritable cases. As BMPRII protein is the major type II receptor for a large family of BMP ligands and expressed ubiquitously in many tissues, dysregulated BMP signalling in other cells may also contribute to PAH pathobiology. Sotatercept, which contains the extracellular domain of another transforming growth factor-β family type II receptor ActRIIA fused to immunoglobin Fc domain, was recently approved by the FDA as a treatment for PAH. Neither its target cells nor its mechanism of action is fully understood. This review will revisit BMPRII function and its extracellular regulation, summarise how dysregulated BMP signalling in endothelial cells and smooth muscle cells may contribute to PAH pathogenesis, and discuss how novel therapeutics targeting the extracellular regulation of BMP signalling, such as BMP9 and Sotatercept, can be related to restoring BMPRII function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- VPD Heart and Lung Research Institute, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0BB, U.K.
ORCID-Profile: Wei Li
Zitieren
APA
Li, W., & Quigley, K. (2024). Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection. Biochemical Society Transactions, 52(3), 1515-1528. https://doi.org/10.1042/bst20231547
Vancouver
Li W, Quigley K. Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection. Biochemical Society Transactions. 2024;52(3):1515-1528. doi:10.1042/bst20231547
BibTeX
@article{Li2024,
author = {Li, Wei and Quigley, Kate},
title = {Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection},
journal = {Biochemical Society Transactions},
year = {2024},
volume = {52},
number = {3},
pages = {1515--1528},
doi = {10.1042/bst20231547}
}
EUVIMED